A phase I and pharmacological study of the matrix metalloproteinase inhibitor BB-3644 in patients with solid tumours

by Wall, L, Talbot, D C, Bradbury, P, Jodrell, D I
Published 2004

Evaluation of rodent-only toxicology for early clinical trials with novel cancer therapeutics

by Newell, D R, Burtles, S S, Fox, B W, Jodrell, D I, Connors, T A
Published 1999

Bolus/infusional 5-fluorouracil and folinic acid for metastatic colorectal carcinoma: are suboptimal dosages being used in the UK?

by Jodrell, D. I., Murray, L. S., Reed, N. S., Canney, P. A., Kaye, S. B., Cassidy, J.
Published 1994

The use of 131I-MIBG in the imaging of metastatic carcinoid tumours.

by Jodrell, D. I., Irvine, A. T., McCready, V. R., Woodcraft, E., Smith, I. E.
Published 1988

Population pharmacokinetics of gentamicin in patients with cancer

by Rosario, M C, Thomson, A H, Jodrell*, D I, Sharp, C A, Elliott, H L
Published 1998

Pharmacokinetic studies with the antifolate C2-desamino-C2-methyl-N10-propargyl-2'-trifluoromethyl-5,8-dideazafolic acid (CB3988) in mice and rats using in vivo 19F-NMR spectroscop...

by Newell, D. R., Maxwell, R. J., Bisset, G. M., Jodrell, D. I., Griffiths, J. R.
Published 1990

Cancer immunotherapy trial registrations increase exponentially but chronic immunosuppressive glucocorticoid therapy may compromise outcomes

by Connell, C. M., Raby, S., Beh, I., Flint, T. R., Williams, E. H., Fearon, D. T., Jodrell, D. I., Janowitz, T.
Published in Ann Oncol (2017)

The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in mice.

by Jodrell, D. I., Newell, D. R., Morgan, S. E., Clinton, S., Bensted, J. P., Hughes, L. R., Calvert, A. H.
Published 1991

5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer

by Jodrell, D I, Stewart, M, Aird, R, Knowles, G, Bowman, A, Wall, L, Cummings, J, McLean, C
Published 2001

Dose-limiting neurotoxicity in a phase I study of penclomedine (NSC 388720, CRC 88-04), a synthetic alpha-picoline derivative, administered intravenously.

by Jodrell, D. I., Bowman, A., Stewart, M., Dunlop, N., French, R., MacLellan, A., Cummings, J., Smyth, J. F.
Published 1998

A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq™ (nolatrexed dihydrochloride) given by 10-day oral administration

by Jodrell, D I, Bowman, A, Rye, R, Byrne, B, Boddy, A, Rafi, I, Taylor, G A, Johnston, A, Clendeninn, N J
Published 1999

In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer

by Aird, R E, Cummings, J, Ritchie, A A, Muir, M, Morris, R E, Chen, H, Sadler, P J, Jodrell, D I
Published 2002

A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer.

by Jodrell, D. I., Smith, I. E., Mansi, J. L., Pearson, M. C., Walsh, G., Ashley, S., Sinnett, H. D., McKinna, J. A.
Published 1991

Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells

by Lin, Y, Richards, F M, Krippendorff, B-F, Bramhall, J L, Harrington, J A, Bapiro, T E, Robertson, A, Zheleva, D, Jodrell, D I
Published 2012

Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma

by Wong, N A C S, Brett, L, Stewart, M, Leitch, A, Longley, D B, Dunlop, M G, Johnston, P G, Lessells, A M, Jodrell, D I
Published 2001

Bolus/infusional 5-fluorouracil and folinic acid. A report on two prospective, consecutive phase II studies with 5-fluorouracil dose escalation.

by Mackean, M. J., Cassidy, J., Jodrell, D. I., Paul, J., Reed, N. S., Canney, P. A., Yosef, H., Habeshaw, T., Robertson, A. G., McInnes, A., Twelves, C. J.
Published 1998

Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo

by Bapiro, T E, Frese, K K, Courtin, A, Bramhall, J L, Madhu, B, Cook, N, Neesse, A, Griffiths, J R, Tuveson, D A, Jodrell, D I, Richards, F M
Published 2014

Fibroblast drug scavenging increases intratumoural gemcitabine accumulation in murine pancreas cancer

by Hessmann, E, Patzak, M S, Klein, L, Chen, N, Kari, V, Ramu, I, Bapiro, T E, Frese, K K, Gopinathan, A, Richards, F M, Jodrell, D I, Verbeke, C, Li, X, Heuchel, R, Löhr, J M, Johnsen, S A, Gress, T M, Ellenrieder, V, Neesse, A
Published in Gut (2018)

Population PKPD of paclitaxel and carboplatin in ovarian cancer patients: A study by the EORTC-PAMM-NDDG

by Joerger, M, Huitema, A D R, Richel, D J, Dittrich, C, Pavlidis, N, Briasoulis, E, Vermorken, J B, Strocchi, E, Martoni, A, Sorio, R, Sleeboom, H P, Izquierdo, M A, Jodrell, D I, Calvert, A H, Boddy, A, Hollema, H, Féty, R, Van der Vijgh, W J F, Hempel, G, Chatelut, E, Karlsson, M, Tranchand, B, Schrijvers, A H G J, Beijnen, J H, Schellens, J H M
Published 2007

Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma

by Corrie, P. G., Qian, W., Basu, B., Valle, J. W., Falk, S., lwuji, C., Wasan, H., Palmer, D., Scott-Brown, M., Wadsley, J., Arif, S., Bridgewater, J., Propper, D., Gillmore, R., Gopinathan, A., Skells, R., Bundi, P., Brais, R., Dalchau, K., Bax, L., Chhabra, A., Machin, A., Dayim, A., McAdam, K., Cummins, S., Wall, L., Ellis, R., Anthoney, A., Evans, J., Ma, Y. T., Isherwood, C., Neesse, A., Tuveson, D., Jodrell, D. I.
Published in Br J Cancer (2020)